UBS Group AG Trims Stake in CG Oncology, Inc. $CGON

UBS Group AG cut its position in CG Oncology, Inc. (NASDAQ:CGON) by 9.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,923,746 shares of the company’s stock after selling 202,524 shares during the quarter. UBS Group AG’s holdings in CG Oncology were worth $79,874,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in CGON. Whittier Trust Co. of Nevada Inc. acquired a new position in CG Oncology during the fourth quarter worth approximately $27,000. Strengthening Families & Communities LLC acquired a new stake in shares of CG Oncology in the third quarter valued at approximately $40,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of CG Oncology by 33.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,920 shares of the company’s stock valued at $163,000 after acquiring an additional 972 shares during the period. Tower Research Capital LLC TRC grew its position in shares of CG Oncology by 159.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock worth $182,000 after acquiring an additional 4,288 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC purchased a new position in shares of CG Oncology during the third quarter worth approximately $208,000. Hedge funds and other institutional investors own 26.56% of the company’s stock.

Insider Buying and Selling at CG Oncology

In other news, Director James Mulay sold 15,600 shares of CG Oncology stock in a transaction dated Friday, April 17th. The shares were sold at an average price of $73.01, for a total value of $1,138,956.00. Following the sale, the director owned 15,600 shares of the company’s stock, valued at $1,138,956. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms recently commented on CGON. HC Wainwright upped their price target on shares of CG Oncology from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, April 7th. The Goldman Sachs Group reissued a “buy” rating and set a $82.00 price objective on shares of CG Oncology in a research report on Monday, January 12th. Piper Sandler lifted their price objective on shares of CG Oncology from $55.00 to $70.00 and gave the company an “overweight” rating in a research note on Friday, January 16th. Morgan Stanley set a $93.00 target price on shares of CG Oncology in a report on Friday, January 9th. Finally, JPMorgan Chase & Co. increased their target price on shares of CG Oncology from $65.00 to $91.00 and gave the stock an “overweight” rating in a research note on Friday, April 17th. Eleven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, CG Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $79.55.

CG Oncology Price Performance

CG Oncology stock opened at $66.27 on Monday. The business has a 50 day simple moving average of $65.06 and a 200-day simple moving average of $52.32. CG Oncology, Inc. has a 12 month low of $21.00 and a 12 month high of $73.56. The stock has a market capitalization of $5.83 billion, a PE ratio of -32.01 and a beta of 0.41.

CG Oncology (NASDAQ:CGON) last posted its quarterly earnings data on Friday, February 27th. The company reported ($0.51) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.10. The firm had revenue of $2.32 million during the quarter. As a group, equities research analysts anticipate that CG Oncology, Inc. will post -2.56 EPS for the current year.

CG Oncology Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.